This article has Open Peer Review reports available.
Herceptin® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis
© The Author(s). 2017
Received: 5 May 2017
Accepted: 28 September 2017
Published: 10 October 2017
Open Peer Review reports
Pre-publication versions of this article are available by contacting firstname.lastname@example.org.
|5 May 2017||Submitted||Original manuscript|
|23 Jun 2017||Reviewed||Reviewer Report - Zahra Madjd|
|14 Jul 2017||Reviewed||Reviewer Report - Xavier Armoiry|
|14 Aug 2017||Author responded||Author comments - Florence Wilson|
|Resubmission - Version 2|
|14 Aug 2017||Submitted||Manuscript version 2|
|31 Aug 2017||Reviewed||Reviewer Report - Xavier Armoiry|
|12 Sep 2017||Author responded||Author comments - Florence Wilson|
|Resubmission - Version 3|
|12 Sep 2017||Submitted||Manuscript version 3|
|22 Sep 2017||Reviewed||Reviewer Report - Xavier Armoiry|
|Resubmission - Version 4|
|Submitted||Manuscript version 4|
|28 Sep 2017||Editorially accepted|
|10 Oct 2017||Article published||10.1186/s13643-017-0588-2|
How does Open Peer Review work?
Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting email@example.com.
You can find further information about the peer review system here.